|
KMID : 0624620220550050205
|
|
BMB Reports
2022 Volume.55 No. 5 p.205 ~ p.212
|
|
|
New therapeutic approach with extracellular vesicles from stem cells for interstitial cystitis/bladder pain syndrome
|
|
Dayem Ahmed Abdal
Song Kwon-Woo
Lee Soo-Bin
Kim A-Ram
Cho Ssang-Goo
|
|
|
Abstract
|
|
|
|
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic disorder characterized by suprapubic pain and urinary symptoms such as urgency, nocturia, and frequency. The prevalence of IC/BPS is increasing as diagnostic criteria become more comprehensive. Conventional pharmacotherapy against IC/BPS has shown suboptimal effects, and consequently, patients with end-stage IC/BPS are subjected to surgery. The novel treatment strategies should have two main functions, anti-inflammatory action and the regeneration of glycosaminoglycan and urothelium layers. Stem cell therapy has been shown to have dual functions. Mesenchymal stem cells (MSCs) are a promising therapeutic option for IC/BPS, but they come with several shortcomings, such as immune activation and tumorigenicity. MSC-derived extracellular vesicles (MSC-EVs) hold numerous therapeutic cargos and are thus a viable cell-free therapeutic option. In this review, we provide a brief overview of IC/BPS pathophysiology and limitations of the MSC-based therapies. Then we provide a detailed explanation and discussion of therapeutic applications of EVs in IC/BPS as well as the possible mechanisms. We believe our review will give an insight into the strengths and drawbacks of EV-mediated IC/BPS therapy and will provide a basis for further development.
|
|
|
KEYWORD
|
|
|
Bladder, Exosome, Extracellular vesicles, IC/BPS, Stem cell
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|